Top Page
Biofrontera
(NASDAQ:BFRI)
Biofrontera (BFRI) vs. SPDR S&P 500 ETF (SPY)
Biofrontera Business Overview & Revenue Model
Biofrontera Earnings Call Summary
Biofrontera Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 37.30M | 34.07M | 28.67M | 24.10M | 18.85M |
| Gross Profit | 18.70M | 16.63M | 13.49M | 11.36M | 9.78M |
| EBITDA | -14.44M | -18.45M | 934.00K | -36.76M | -7.49M |
| Net Income | -17.76M | -20.13M | -640.00K | -37.71M | -10.99M |
Balance Sheet | |||||
| Total Assets | 22.10M | 27.93M | 50.88M | 53.22M | 24.14M |
| Cash, Cash Equivalents and Short-Term Investments | 5.91M | 1.42M | 27.76M | 24.55M | 8.08M |
| Total Debt | 4.92M | 5.40M | 1.35M | 0.00 | 0.00 |
| Total Liabilities | 17.67M | 23.14M | 27.00M | 41.88M | 18.31M |
| Stockholders Equity | 4.43M | 4.79M | 23.88M | 11.34M | 5.83M |
Cash Flow | |||||
| Free Cash Flow | -10.28M | -24.90M | -16.24M | -26.73M | -12.37M |
| Operating Cash Flow | -10.27M | -24.89M | -16.20M | -26.71M | -12.37M |
| Investing Cash Flow | -3.00K | 619.00K | -5.16M | -11.00K | 0.00 |
| Financing Cash Flow | 14.84M | 8.41M | 14.02M | 43.19M | 13.19M |
Biofrontera Technical Analysis
Biofrontera Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $13.39M | ― | 3.29% | ― | -26.17% | ― | |
52 Neutral | $7.39B | >-0.01 | -63.86% | 2.36% | 16.15% | 0.36% | |
49 Neutral | $7.75M | ― | -384.98% | ― | 14.27% | 87.31% | |
46 Neutral | $13.16M | ― | -58.30% | ― | ― | ― | |
46 Neutral | $6.87M | ― | -21.17% | ― | 35.51% | 95.44% | |
40 Neutral | $5.55M | ― | -59.14% | ― | -33.10% | 71.37% |
Biofrontera Corporate Events
On June 30, 2025, Biofrontera Inc. finalized an agreement with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a royalty payment structure and grants Biofrontera AG a 10% equity stake in Biofrontera Inc. through Series D Convertible Preferred Stock. Additionally, a private placement of Series C Preferred Stock was initiated on June 27, 2025, to fund the acquisition, with proceeds expected to reach $11 million. This move is expected to enhance Biofrontera Inc.’s market presence in the U.S. and streamline its operations by consolidating rights to its key products.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On June 30, 2025, Biofrontera Inc. announced a significant restructuring of its relationship with Biofrontera AG, acquiring all U.S. rights to Ameluz® and RhodoLED® backed by an $11 million investment led by existing investors. This agreement reduces the royalty rate on Ameluz® sales, aiming to drive the company towards profitability and strengthen its presence in the U.S. dermatology market. The restructuring allows Biofrontera Inc. to assume full control over manufacturing, regulatory, and commercial responsibilities in the U.S., aligning long-term interests with Biofrontera AG through a 10% equity stake. The move is expected to enhance operational agility and support the company’s growth strategy, including an upcoming FDA submission for treating superficial basal cell carcinoma.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On June 12, 2025, Biofrontera Inc. held its Annual Meeting of Stockholders, where key decisions were made to shape the company’s future. Stockholders elected Heikki Lanckriet as a Class I director, approved an increase in authorized common stock shares, agreed to adjourn the meeting if necessary for further proxy solicitation, and ratified the appointment of CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to enhance Biofrontera’s operational capabilities and strategic positioning in the biotechnology sector.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On June 11, 2025, Biofrontera Inc. announced that it is in negotiations with Biofrontera AG regarding potential changes to their cooperation, including a possible combination of the two companies or adjustments to their license and supply agreement. These negotiations could lead to the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc., as well as a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the U.S. The terms of any agreement are yet to be finalized and are subject to numerous conditions.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On June 3, 2025, Biofrontera Inc. filed a supplement to its Proxy Statement to update stockholders on voting procedures for their 2025 Annual Meeting. The supplement clarifies that Proposals 2 and 3 are considered routine matters under NYSE rules, allowing brokers to vote on them without instructions from shareholders, contrary to previous disclosures. Stockholders are urged to review these changes and vote accordingly.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On May 21, 2025, Biofrontera Inc. received a notice from Nasdaq indicating non-compliance with the equity listing requirement, as their stockholders’ equity was reported at $469,000, below the required $2,500,000. The company has 45 days to submit a compliance plan to Nasdaq, and if accepted, they may have up to 180 days to meet the requirements, with the possibility of appealing if the plan is rejected.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On May 8, 2025, Biofrontera Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock had closed below $1.00 per share for 33 consecutive business days. The company has until November 5, 2025, to regain compliance by ensuring its stock price meets the minimum requirement for 10 consecutive business days. Biofrontera is actively monitoring its stock price and considering options to address the deficiency, although there is no guarantee of compliance.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.